Abbott has received CE Mark for its new Confirm Rx Insertable Cardiac Monitor (ICM) that will help physicians identify cardiac arrhythmias that are difficult to detect, including atrial fibrillation (AF).

Being the world’s first smartphone-compatible ICM, the new system is designed to continuously monitor a patient's heart rhythm and immediately transmit information via the myMerlin mobile app. This enables physicians to follow their patients remotely and diagnose arrhythmias accurately.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

With the launch of the Confirm Rx ICM in European CE Mark countries, the company has incorporated a new wireless technology that enables the ICM to communicate directly and securely to the app downloaded onto a patient's smartphone.

The latest myMerlin mobile app helps replace the heavy handheld or bedside transmitters that are required for traditional remote monitoring and which limit a patient’s mobility.

The interactive app allows patients to participate in their own care.

See Also:

Slimmer than currently available ICMs, the new Confirm Rx ICM provides simple, easy and intuitive one-touch indication-based programming, as well as remote monitoring via the Merlin.net Patient Care Network.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The myMerlin mobile app is currently available in more than 35 languages and facilitates patients to stay easily connected to their physicians.

"Incorporating wireless technology directly into our devices enhances the quality of remote monitoring and patient compliance."

Patients can record their symptoms on their own smartphone, while they can confirm a secure transmission of data to their physician and get automatic alerts when they miss a scheduled transmission.

Abbott Cardiac Arrhythmias and Neuromodulation Businesses chief medical officer Dr Mark Carlson said: “Incorporating wireless technology directly into our devices enhances the quality of remote monitoring and patient compliance.

“The Confirm Rx ICM addresses a broad range of indications, such as syncope, palpitations and atrial fibrillation. The technology has been designed with robust data privacy and security measures to ensure peace of mind for both patients and providers.”

Since CE Mark approval, the Confirm Rx device has been deployed in 10 countries across Europe.

Image: The Abbott Confirm Rx ICM is the world’s first smartphone-enabled insertable cardiac monitor, providing powerful data to help monitor irregular heartbeats, unexplained syncope, palpitations and atrial fibrillation. Photo: courtesy of PR Newswire.